Ehrlich and colleagues developed an immunotoxin named BW-2, consisting of an antibody against a RNA-binding protein in neurons called HuD and the toxin saporin, for the treatment of SCLC and neuroblastoma in HuD-expressing cancer cells and tumor models. This evidence concerns the gene ELAVL4 and neoplasm.